ReviewFrontiers in immunology2025
Anti-inflammatory effects of natural polysaccharides: molecular mechanisms and nanotherapeutic applications.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Optimization of pressure-assisted enzymatic treatment for fiber solubilization and structural modification of Korean cabbage by-products.Food chemistry: X · 2026Article
- Advances in Bioactive Polysaccharide-Small-Molecule Drug Supramolecular Nanocomplexes for Drug Delivery and Therapeutic Applications.Journal of functional biomaterials · 2026Review
- Structural Characterization and Anti-Inflammatory Effects in LPS-Stimulated RAW264.7 Macrophages of an Inulin-Type Fructan (AVP-1-2) Isolated fromPlants (Basel, Switzerland) · 2026Article
- Natural Polysaccharide-Mediated Nano-Delivery Systems for Osteoporosis Therapy From a Gut-Bone Axis Regulatory Perspective.Advanced healthcare materials · 2026Review
- Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).Molecular medicine reports · 2026Review
- Natural polysaccharides as immunometabolic modulators in metabolic diseases: mechanisms and translational challenges.Frontiers in immunology · 2026Review
- Digestive properties in fermentation driven interactions of plant polysaccharides with gut microbiota and their health implications.Frontiers in pharmacology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic excessive inflammation drives the pathogenesis of diseases such as Heart Failure (HF) and arthritis. Natural polysaccharides, with low toxicity and biodegradability, exert anti-inflammatory effects by regulating core inflammatory signaling pathways (e.g., Nuclear Factor-κB (NF-κB), Mitogen-Activated Protein Kinase (MAPK), Toll-Like Receptor (TLR)) and downregulating pro-inflammatory cytokines including Tumor Necrosis Factor-α (TNF-α), IL-1β, and IL-6. But their poor water solubility and easy breakdown by digestive enzymes limit bioavailability. Nanonization solves these problems by enhancing aqueous dispersibility, reducing enzymatic hydrolysis, and improving targeting efficiency (passive via the Enhanced Permeability and Retention (EPR) effect, active via ligand modification). It also strengthens the inhibition of pro-inflammatory pathways, activates the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)/Heme Oxygenase-1 (HO-1) antioxidant pathway, and protects the mucosal barrier. This review is divided into four logical sections-fundamental mechanisms of inflammation and polysaccharide regulation, anti-inflammatory activities of natural polysaccharides, nanonization strategies for efficacy enhancement, and clinical translation potential. It eliminates redundancy, integrates overlapping information, and provides a concise framework to promote the clinical application of polysaccharide-based anti-inflammatory therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.